Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101580 · ClinicalTrials.gov registry record · Phase 1
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
A Phase 1 study of Advanced Pancreatic Cancer, sponsored by Polaris Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02101580: Completed Phase 1 study of Advanced Pancreatic Cancer, sponsored by Polaris Group.
NCT02101580 is a Phase 1 study of Advanced Pancreatic Cancer that has completed, run by Polaris Group. The registered enrollment target is 21 participants, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02101580, a Phase 1 study of Advanced Pancreatic Cancer, has completed, sponsored by Polaris Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
Conditions Studied
Interventions
- DRUG ADI-PEG 20
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 1 |
What the finished NCT02101580 record still lists
NCT02101580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT02101580 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02101580 about?
NCT02101580 is a clinical study titled "Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer". Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
What is the current status of trial NCT02101580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-11-17. Estimated completion is 2017-10-06.
What conditions does trial NCT02101580 study?
This clinical trial studies the following conditions: Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT02101580?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT02101580?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02101580 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI